honokiol has been researched along with Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y; Huang, X; Li, B; Li, HM; Li, Y; Ma, H; Wang, H; Wu, CZ; Zhu, M | 1 |
| Kalyanaraman, B | 1 |
| Alshahrani, AM; Ateşşahin, DA; Calina, D; Fatima, R; Prasher, P; Sharifi-Rad, J; Sharma, M; Tynybekov, B | 1 |
| Chen, SZ | 1 |
| Arfuso, F; Banik, K; Bordoloi, D; Deshpande, V; Fan, L; Kunnumakkara, AB; Nalawade, SP; Padmavathi, G; Ranaware, AM; Sailo, BL; Sethi, G; Shanmugam, MK | 1 |
| Chaudhary, A; Kumar Singh, U; Kumar, A | 1 |
| Arbiser, JL; Bonner, MY; Brady, C; Hawkins, AR; Lamb, HK; Lefkove, B; Lovat, PE; Martin, S; Redfern, CP; Thompson, P | 1 |
| Amin, AR; Arbiser, JL; Beitler, JJ; Bonner, M; Chen, ZG; Huang, W; Koenig, L; Lee, MJ; Nannapaneni, S; Shin, DM; Shin, HJ; Wang, H; Wang, X | 1 |
| Mukherji, M; Subhani, S; Vavilala, DT | 1 |
| Lee, Y; Pan, J; Wang, Y; You, M | 1 |
| Katiyar, SK; Prasad, R | 1 |
| Arbiser, JL; Bar-Sagi, D; Brown, HA; Fan, J; Foster, DA; Garcia, A; Shraibman, N; Toschi, A; Zhao, C; Zheng, Y | 1 |
| Kapoor, S | 1 |
| Chen, MY; Hsu, FC; Lan, KH; Lan, KL; Liu, RS; Sheu, ML; Shih, YS; Wang, HM; Yen, SH | 1 |
| Guo, D; He, R; Li, Q; Li, R; Lin, X; Qiao, X; Xiang, C; Ye, M | 1 |
| Arora, S; Contreras, CM; Panyam, J; Piazza, GA; Singh, AP; Singh, S | 1 |
| Gu, Y; Han, W; Hu, X; Jin, J; Li, L; Lu, Q; Luo, J; Qiu, S | 1 |
9 review(s) available for honokiol and Neoplasms
| Article | Year |
|---|---|
Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.
Topics: Atovaquone; Biphenyl Compounds; Black People; Health Status Disparities; Hispanic or Latino; Humans; Immune Checkpoint Inhibitors; Lignans; Mitochondria; Neoplasms; Oxidative Phosphorylation; Tumor Microenvironment | 2022 |
Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship.
Topics: Biphenyl Compounds; Cell Line, Tumor; Humans; Lignans; Neoplasms; Phenols; Structure-Activity Relationship | 2023 |
[Research progress in anticancer effects and molecular targets of honokiol in experimental therapy].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Synergism; Humans; Lignans; Neoplasms; Signal Transduction; Therapies, Investigational | 2016 |
Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Humans; Lignans; Magnolia; Molecular Targeted Therapy; Neoplasms | 2019 |
Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities.
Topics: Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Caspases; Humans; Lignans; Magnolia; Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phospholipase D; Signal Transduction; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2013 |
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Anthracyclines; Biphenyl Compounds; Cardiac Glycosides; Humans; Hypoxia-Inducible Factor 1; Indazoles; Lignans; Models, Biological; Neoplasms; Neovascularization, Pathologic; Retinal Neovascularization; Vascular Endothelial Growth Factors | 2016 |
Honokiol targets mitochondria to halt cancer progression and metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lignans; Magnolia; Mitochondria; Neoplasms; Plant Extracts; Polyphenols | 2016 |
Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Cell Proliferation; Humans; Lignans; Neoplasms; Signal Transduction; Ultraviolet Rays | 2016 |
Honokiol: a novel natural agent for cancer prevention and therapy.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; ErbB Receptors; Humans; Lignans; Magnolia; Mice; Neoplasms; NF-kappa B; Plant Preparations; Rats; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases | 2012 |
8 other study(ies) available for honokiol and Neoplasms
| Article | Year |
|---|---|
Synthesis and in vitro antitumor evaluation of honokiol derivatives.
Topics: Antineoplastic Agents; Biphenyl Compounds; Humans; Lignans; Neoplasms | 2020 |
Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biphenyl Compounds; Catechin; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Lignans; Molecular Targeted Therapy; Molecular Weight; Neoplasms; Protein Binding | 2013 |
Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Ki-67 Antigen; Lignans; Mitochondria; Neoplasms; Paclitaxel; Receptors, Death Domain; Signal Transduction; STAT3 Transcription Factor | 2014 |
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Enzyme Activation; Humans; Lignans; Mice; Models, Chemical; Neoplasm Transplantation; Neoplasms; Phospholipase D; ras Proteins; Signal Transduction | 2008 |
Antineoplastic effects of Magnoliae officinalis in tumours other than hepatomas.
Topics: Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Humans; Lignans; Magnolia; Neoplasms; Plant Extracts | 2009 |
Honokiol inhibits hypoxia-inducible factor-1 pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Cobalt; Enzyme-Linked Immunosorbent Assay; Female; HeLa Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Immunohistochemistry; Lignans; Luciferases; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms | 2011 |
Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry.
Topics: Animals; Area Under Curve; Biphenyl Compounds; Chromatography, Liquid; Curcumin; Diarylheptanoids; Drug Delivery Systems; Drug Stability; Lignans; Linear Models; Lipids; Male; Mice; Mice, Inbred ICR; Nanoparticles; Neoplasm Transplantation; Neoplasms; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis Inducing Factor; Biphenyl Compounds; Cell Death; Cell Line, Tumor; Cell Nucleus; Cyclophilins; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lignans; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Necrosis; Neoplasms; Reactive Oxygen Species | 2007 |